A5015522451- Dermatology and Skin Diseases
- Psoriasis: Treatment and Pathogenesis
- Urticaria and Related Conditions
- Asthma and respiratory diseases
- Allergic Rhinitis and Sensitization
- Autoimmune Bullous Skin Diseases
- Mast cells and histamine
- T-cell and B-cell Immunology
- Estrogen and related hormone effects
- Antimicrobial Peptides and Activities
- Cytokine Signaling Pathways and Interactions
- Immune Response and Inflammation
- Food Allergy and Anaphylaxis Research
- Systemic Lupus Erythematosus Research
- Nail Diseases and Treatments
- Monoclonal and Polyclonal Antibodies Research
- Pharmacological Effects of Natural Compounds
- Spondyloarthritis Studies and Treatments
- IL-33, ST2, and ILC Pathways
- Glycosylation and Glycoproteins Research
- Immunodeficiency and Autoimmune Disorders
- Immune Cell Function and Interaction
- Cancer and Skin Lesions
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Drug-Induced Adverse Reactions
Chiba Hokusou Hospital
2018-2025
Teikyo University
2008-2021
Sapporo Kosei General Hospital
2015-2017
Aoyama Gakuin University
2013
Teikyo University Hospital
2003
The University of Tokyo
1996-2002
Keio University
1998
Social Insurance Saitama Chuo Hospital
1997
Bimekizumab, which suppresses both interleukin (IL)-17A and IL-17F, has recently been approved as a biologic for psoriasis. We aimed to evaluate the real-world effectiveness safety of bimekizumab psoriasis identify predictive factors its treatment responsiveness. analyzed 36 Japanese patients with (19 vulgaris 17 psoriatic arthritis) from May 2022 September 2023. All received (320 mg every 4 weeks) until week 16. Seventeen (43.2%) had experienced bio-switch. The median (interquartile range)...
Abstract: Background: Real-world data on the effectiveness and safety of lebrikizumab for atopic dermatitis (AD) are limited.
Abstract We studied the in vitro effect of testosterone on spontaneous immunoglobulin production by human peripheral blood mononuclear cells (PBMC). Testosterone inhibited IgG and IgM PBMC both from males females. The inhibitory was revealed at doses more than 1 nm, increased dose-dependently, reached a plateau 100 nm. At <1000 did not reduce cell viability. treatment reduced 59.0% that 61.3% compared with control. Immunoglobulin B also suppressed testosterone, though magnitude...
IL-18 is involved in the pathogenesis of atopic dermatitis, psoriasis, and allergic contact dermatitis. CXCL9, CXCL10, CXCL11 recruit type 1 T cells, production these chemokines by keratinocytes enhanced dermatoses. We examined vitro effects on IFN-gamma-induced human keratinocytes. secretion mRNA expression parallel to activation NF-kappaB, STAT1, IFN-regulatory factor (IRF)-1. Antisense oligonucleotides against NF-kappaB p50, p65, or STAT1 suppressed production, antisense IRF-1 production....
Abstract We evaluated the efficacy and safety of upadacitinib, janus kinase 1 inhibitor for atopic dermatitis (AD) in real‐world practice. From September 2021 to March 2022, 31 patients with moderate‐to‐severe AD, aged ≥12 years were treated oral upadacitinib 15 mg/day plus topical corticosteroids. Upadacitinib reduced clinical indexes compared baseline levels: percent reduction at week 4 12 (median) was 73.6% 85.6% eczema area severity index (EASI); 81.3% AD control tool (ADCT); 70% 75%...
Abstract The authors evaluated the efficacy and safety of baricitinib, a Janus kinase 1/2 inhibitor, for atopic dermatitis (AD) in real‐world practice. From August 2021 to September 2022, 36 patients aged ≥15 years with moderate severe AD were treated oral baricitinib 4 mg/day plus topical corticosteroids. Baricitinib improved clinical indexes; percent reduction at weeks 12 was median 69.19% 69.98% Eczema Area Severity Index (EASI), 84.52% 76.33% Atopic Dermatitis Control Tool, 76.39% 64.58%...
Psoriasis is associated with cardiometabolic and cardiovascular diseases. Biologic therapy targeting tumor necrosis factor (TNF)-α, interleukin (IL)-23, IL-17 may improve not only psoriasis but also We retrospectively evaluated whether biologic improved various indicators of disease. Between January 2010 September 2022, 165 patients were treated biologics TNF-α, IL-17, or IL-23. The patients’ body mass index; serum levels HbA1c, total cholesterol, high-density lipoprotein-cholesterol...
Atopic dermatitis (AD) is a chronic inflammatory skin disease with severe itch. The eosinophil-to-lymphocyte ratio (ELR), neutrophil-to-lymphocyte (NLR), monocyte-to-lymphocyte (MLR), and platelet-to-lymphocyte (PLR) are reported to reflect itch or the severity of AD. We examined if these parameters may act as indicators for therapeutic effects Janus kinase 1 inhibitor upadacitinib patients AD in real-world clinical practice. Between August 2021 September 2023, 65 Japanese (aged ≥ 12 years)...
Previous clinical trials presented efficacy and safety of Janus kinase 1 inhibitor upadacitinib through 52 weeks for moderate-to-severe atopic dermatitis (AD).
Background Janus kinase 1 inhibitor upadacitinib is therapeutically effective for atopic dermatitis (AD). However, predictive factors high responders to have not been established in real-world clinical practice.
Atopic dermatitis (AD) is a chronic skin disease characterized by type 2-skewed immune responses, and significantly influenced cytokines dependent on Janus kinases (JAKs). Upadacitinib, JAK1 inhibitor, effective for moderate-to-severe AD. This study aims to identify biomarkers that reflect long-term therapeutic effects of upadacitinib 15 mg or 30 mg. A retrospective from August 2021 July 2023 included 213 AD patients treated with 70 We analyzed eczema area severity index (EASI), peak...
Background Deucravacitinib is a selective oral tyrosine kinase 2 (TYK2) inhibitor recently approved for psoriasis.
Abstract Psoriasis is a complex, chronic inflammatory skin disease that significantly impacts patients' quality of life (QOL), especially in cases genital, nail, and scalp psoriasis. Bimekizumab an inhibitor interleukin (IL)‐17A IL‐17F used for the treatment The aim this retrospective study was to evaluate effectiveness bimekizumab through treating lesions with psoriasis over 24 weeks. conducted from May 2022 February 2024 on 52 patients treated bimekizumab. therapeutic effects were...
Tralokinumab, a monoclonal anti-IL-13 antibody, is approved for treating atopic dermatitis (AD). Real-world data on its effectiveness and safety are limited.
To study the in vitro effect of estrogen on IgG anti-double-stranded DNA (anti-dsDNA) antibody and total production peripheral blood mononuclear cells (PBMC) from patients with systemic lupus erythematosus (SLE), order to elucidate its regulatory role SLE.PBMC SLE normal donors were cultured 17beta-estradiol (E2). anti-dsDNA antibodies, IgG, cytokine activity culture supernatants measured by enzyme-linked immunosorbent assay.E2 enhanced antibodies as well PBMC patients. Anti-dsDNA inactive...
Psoriasis is a chronic inflammatory skin disease characterized by IL-17-dominant abnormal innate and acquired immunity, the hyperproliferation aberrant differentiation of epidermal keratinocytes, comorbid arthritis or cardiometabolic diseases. This Special Issue presented updated information on pathogenesis, comorbidities, therapy psoriasis. The pathogenesis psoriasis may involve dysfunction indoleamine 2,3-dioxygenase 2 UBA domain containing 1-mediated regulation CARD14/CARMA2sh. blood...